Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
暂无分享,去创建一个
A. Troxel | R. Clark | R. Watanabe | I. Kirsch | J. Gelfand | C. Surber | Ellen J. Kim | A. Rook | M. Wysocka | B. Benoit | R. Elenitsas | M. A. Buchanan | Deborah Leahy | M. Buchanan